Linked Life Data

10955805

Source:http://linkedlifedata.com/resource/pubmed/id/10955805

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10955805rdf:typepubmed:Citationlld:pubmed
pubmed-article:10955805lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:10955805lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:10955805lifeskim:mentionsumls-concept:C0242643lld:lifeskim
pubmed-article:10955805lifeskim:mentionsumls-concept:C0069906lld:lifeskim
pubmed-article:10955805lifeskim:mentionsumls-concept:C0085415lld:lifeskim
pubmed-article:10955805lifeskim:mentionsumls-concept:C1537044lld:lifeskim
pubmed-article:10955805pubmed:issue8lld:pubmed
pubmed-article:10955805pubmed:dateCreated2000-11-27lld:pubmed
pubmed-article:10955805pubmed:abstractTextDespite treatment with intensive chemotherapy, a considerable number of patients with acute myeloid leukemia (AML) die from their disease due to the occurrence of resistance. Overexpression of the transporter proteins P-glycoprotein (P-gp) and multidrug resistance protein (MRP) 1 has been identified as a major cause of cross-resistance to functionally and structurally unrelated drugs. In the present study, the functional activity of P-gp and MRP was determined in 104 de novo AML patients with a flow cytometric assay using rhodamine 123 (Rh123) in combination with PSC833 and carboxyfluorescein (CF) in combination with MK-571. The results were compared with clinical outcome and with known prognostic factors. The functional activity of P-gp and MRP, expressed as Rh123 efflux blocking by PSC833 and CF efflux blocking by MK-571, demonstrated a great variability in the AML patients. A strong negative correlation was observed between Rh123 efflux blocking by PSC833 and Rh123 accumulation (r(s) = -0.69, P < 0.001) and between CF efflux blocking by MK-571 and CF accumulation (r(s) = -0.59, P < 0.001). A low Rh123 accumulation and a high Rh123 efflux blocking by PSC833 were associated with a low complete remission (CR) rate after the first cycle of chemotherapy (P = 0.008 and P = 0.01, respectively). Patients with both low Rh123 and CF accumulation (n = 16) had the lowest CR rate (6%), whereas patients with both high Rh123 and CF accumulation (n = 11) had a CR rate of 73%. AML patients with French-American-British classification M1 or M2 showed a lower Rh123 accumulation than patients with French-American-British classification M4 or M5 (P = 0.02). No association was observed between the multidrug resistance parameters and overall survival of the AML patients. Risk group was the only predictive parameter for overall survival (P = 0.003).lld:pubmed
pubmed-article:10955805pubmed:languageenglld:pubmed
pubmed-article:10955805pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:citationSubsetIMlld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10955805pubmed:statusMEDLINElld:pubmed
pubmed-article:10955805pubmed:monthAuglld:pubmed
pubmed-article:10955805pubmed:issn1078-0432lld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:VellengaEElld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:VerhoefG EGElld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:OssenkoppeleG...lld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:de VriesE GEGlld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:VerdonckL FLFlld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:van PuttenW...lld:pubmed
pubmed-article:10955805pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:10955805pubmed:issnTypePrintlld:pubmed
pubmed-article:10955805pubmed:volume6lld:pubmed
pubmed-article:10955805pubmed:ownerNLMlld:pubmed
pubmed-article:10955805pubmed:authorsCompleteYlld:pubmed
pubmed-article:10955805pubmed:pagination3205-14lld:pubmed
pubmed-article:10955805pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:meshHeadingpubmed-meshheading:10955805...lld:pubmed
pubmed-article:10955805pubmed:year2000lld:pubmed
pubmed-article:10955805pubmed:articleTitleP-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.lld:pubmed
pubmed-article:10955805pubmed:affiliationDepartment of Hematology, University Hospital Groningen, the Netherlands.lld:pubmed
pubmed-article:10955805pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10955805lld:pubmed